# The Safety and Immunogenicity of SCTV01C in Healthy Population Aged ≥18 Years Previously Vaccinated With mRNA COVID-19 Vaccine.

> **NCT05043311** · PHASE1,PHASE2 · UNKNOWN · sponsor: **Sinocelltech Ltd.** · enrollment: 300 (estimated)

## Conditions studied

- COVID-19
- SARS-CoV-2 Infection

## Interventions

- **BIOLOGICAL:** SCTV01C
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT05043311
- **Lead sponsor:** Sinocelltech Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-12-22
- **Primary completion:** 2022-06-01
- **Final completion:** 2023-01-01
- **Target enrollment:** 300 (ESTIMATED)
- **Last updated:** 2022-01-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05043311

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05043311, "The Safety and Immunogenicity of SCTV01C in Healthy Population Aged ≥18 Years Previously Vaccinated With mRNA COVID-19 Vaccine.". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT05043311. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*